[1]	Wu Y, Fan L, Shao H, et al. Evaluation of a novel ensemble model for preoperative ovarian cancer diagnosis:Clinical factors,O-RADS,and deep learning radiomics[J]. Transl Oncol, 2025,54:102335. DOI:10.1016/j.tranon.2025.102335. Cited in this article [2]

[2]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 35 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. DOI:10.3322/caac.21834. Cited in this article [1]

[3]	Gao Y, Zeng S, Xu X, et al. Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China:a retrospective,multicentre,diagnostic study[J]. Lancet Digit Health, 2022, 4(3):e179-e187. DOI:10.1016/S2589-7500(21)00278-8. Cited in this article [1]

[4]	Wang YS, Ren SF, Jiang W, et al. CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels[J]. Ann Transl Med, 2021, 9(9):788. DOI:10.21037/atm-20-8053. Cited in this article [1]

[5]	Jain S, Nadeem N, Ulfenborg B, et al. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer[J]. Int J Cancer, 2022, 151(7):1175-1184. DOI:10.1002/ijc.34111. Cited in this article [1]

[6]	Wu X, Li D, Liu L, et al. Serum soluble mesothelin-related peptide (SMRP):a potential diagnostic and monitoring marker for epithelial ovarian cancer[J]. Arch Gynecol Obstet, 2014, 289(6):1309-1314. DOI:10.1007/s00404-013-3128-x. Cited in this article [1]

[7]	Pearl ML, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 134(3):581-590. DOI:10.1016/j.ygyno.2014.06.013. Cited in this article [1]

[8]	Zhang X, Li H, Yu X, et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker[J]. Cell Physiol Biochem, 2018, 48(5):1983-1994. DOI:10.1159/000492521. Cited in this article [1]

[9]	Meng X, Müller V, Milde-Langosch K, et al. Circulating cell-free miR-373,miR-200a,miR-200b and miR-200c in patients with epithelial ovarian cancer[J]. Adv Exp Med Biol, 2016,924:3-8. DOI:10.1007/978-3-319-42044-8_1. Cited in this article [1]

[10]	Ali FT, Soliman RM, Hassan NS, et al. Sensitivity and specificity of microRNA-204,CA125,and CA19.9 as biomarkers for diagnosis of ovarian cancer[J]. PLoS ONE, 2022, 17(8):e0272308. DOI:10.1371/journal.pone.0272308. Cited in this article [1]

[11]	Zhu Z, Chen Z, Wang M, et al. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging[J]. J Ovarian Res, 2022, 15(1):27. DOI:10.1186/s13048-022-00961-x. Cited in this article [1]

[12]	Pei CL, Fei KL, Yuan XY, et al. LncRNA DANCR aggravates the progression of ovarian cancer by downregulation UPF1[J]. Eur Rev Med Pharmacol Sci, 2019, 23(24):10657-10663. DOI:10.26355/eurrev_201912_19763. Cited in this article [1]

[13]	Yang M, Zhai Z, Guo S, et al. Long non-coding RNA FLJ33360 participates in ovarian cancer progression by sponging miR-30b-3p[J]. Onco Targets Ther, 2019, 12:4469-4480. DOI:10.2147/OTT.S205622. Cited in this article [1]

[14]	Hu Y, Zhu Y, Zhang W, et al. Utility of plasma circBNC2 as a diagnostic biomarker in epithelial ovarian cancer[J]. Onco Targets Ther, 2019, 12:9715-9723. DOI:10.2147/OTT.S211413. Cited in this article [1]

[15]	Ning L, Lang J, Wu L. Plasma circN4BP2l2 is a promising novel diagnostic biomarker for epithelial ovarian cancer[J]. BMC Cancer, 2022, 22(1):6. DOI:10.1186/s12885-021-09073-z. Cited in this article [1]

[16]	Chen K, Shields MD, Chauhan PS, et al. Commercial ctDNA assays for minimal residual disease detection of solid tumors[J]. Mol Diagn Ther, 2021, 25(6):757-774. DOI:10.1007/s40291-021-00559-x. Cited in this article [1]

[17]	Keserű JS, Soltész B, Lukács J, et al. Detection of cell-free,exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer[J]. J Biotechnol, 2019, 298:76-81. DOI:10.1016/j.jbiotec.2019.04.015. Cited in this article [1]

[18]	Meng X, Schwarzenbach H, Yang Y, et al. Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer[J]. Transl Oncol, 2019, 12(9):1213-1220. DOI:10.1016/j.tranon.2019.05.015. Cited in this article [1]

[19]	Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas:a proof-of-concept study[J]. J Clin Oncol, 2015, 33(36):4293-4300. DOI:10.1200/JCO.2015.61.3083. Cited in this article [1]

[20]	Ghezelayagh TS, Kohrn BF, Fredrickson J, et al. Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer[J]. Cancer Res Commun, 2022, 2(10):1282-1292. DOI:10.1158/2767-9764.crc-22-0314. Cited in this article [1]

[21]	Gao Y, Liu CJ, Li HY, et al. Platelet RNA enables accurate detection of ovarian cancer:an intercontinental,biomarker identification study[J]. Protein Cell, 2023, 14(6):579-590. DOI:10.1093/procel/pwac056. Cited in this article [1]

[22]	Cooper TT, Dieters-Castator DZ, Liu J, et al. Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer[J]. J Ovarian Res, 2024, 17(1):149. DOI:10.1186/s13048-024-01471-8. Cited in this article [1]

[23]	Liu W, Hu X, Bao Z, et al. Serum metabolic fingerprints encode functional biomarkers for ovarian cancer diagnosis:a large-scale cohort study[J]. EBioMedicine, 2025,15:105706. DOI:10.1186/s13048-024-01471-8. Cited in this article [1]

[24]	明澜, 程凯, 陈钰, 等. 卵巢癌诊断性分子探针的研究进展[J]. 中国医药导报, 2020, 17(32):36-39. DOI:10.20047/j.issn1673-7210.2020.32.010. Cited in this article [2]

[25]	Christiansen F, Konuk E, Ganeshan AR, et al. International multicenter validation of AI-driven ultrasound detection of ovarian cancer[J]. Nat Med, 2025, 31(1):189-196. DOI:10.1038/s41591-024-03329-4. Cited in this article [1]

[26]	Chen J, Yang F, Liu C, et al. Diagnostic value of a CT-based radiomics nomogram for discrimination of benign and early stage malignant ovarian tumors[J]. Eur J Med Res, 2023, 28(1):609. DOI:10.1186/s40001-023-01561-1. Cited in this article [1]

[27]	Song XL, Ren JL, Zhao D, et al. Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features:the value of precision diagnosis ovarian neoplasms[J]. Eur Radiol, 2021, 31(1):368-378. DOI:10.1007/s00330-020-07112-0. Cited in this article [1]

[28]	Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population[J]. Best Pract Res Clin Obstet Gynaecol, 2012, 26(2):243-56. DOI:10.1016/j.bpobgyn.2011.11.006. Cited in this article [1]

[29]	中国老年保健协会妇科肿瘤专业委员会, 中国医师协会妇产科医师分会. 卵巢癌早期筛查中国专家共识(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(2):204-211. DOI:10.19538/j.fk2025020113. Cited in this article [1]

[30]	Cui R, Wang Y, Li Y, et al. Clinical value of ROMA index in diagnosis of ovarian cancer:meta-analysis[J]. Cancer Manag Res, 2019, 11:2545-2551. DOI:10.2147/CMAR.S199400. Cited in this article [1]

[31]	Suri A, Perumal V, Ammalli P, et al. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients:a meta-analysis[J]. Sci Rep, 2021, 11(1):17308. DOI:10.1038/s41598-021-96552-9. Cited in this article [1]

[32]	中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31 (6):490-500. DOI:10.19401/j.cnki.1007-3639.2021.06.07. Cited in this article [1]

[33]	Yamanaka S, Kawahara N, Kawaguchi R, et al. The comparison of three predictive indexes to discriminate Malignant ovarian tumors from benign ovarian endometrioma:the characteristics and efficacy[J]. Diagnostics, 2022, 12(5):1212. DOI:10.3390/diagnostics12051212. Cited in this article [1]

[34]	Barreñada L, Ledger A, Dhiman P, et al. ADNEX risk prediction model for diagnosis of ovarian cancer:systematic review and meta- analysis of external validation studies[J]. BMJ Medicine, 2024, 3(1):e000817. DOI:10.1136/bmjmed-2023-000817. Cited in this article [1]

[35]	倪丽, 王莹莹, 朱晨辰, 等. 卵巢癌高风险患者行预防性手术105例临床资料分析[J]. 中国实用妇科与产科杂志, 2025, 41(7):738-741.DOI:10.19538/j.fk2025070115. Cited in this article [1]

[36]	曹瑢, 陈刚. 卵巢恶性肿瘤随访[J]. 中国实用妇科与产科杂志, 2024, 40(11):1091-1093.DOI:10.19538/j.fk2024110109. Cited in this article [1]

[37]	张杰, 王登凤, 张国楠. 卵巢恶性肿瘤多学科团队诊治——基于四川省肿瘤医院妇科肿瘤团队经验[J]. 中国实用妇科与产科杂志, 2024, 40(11):1065-1069.DOI:10.19538/j.fk2024110103. Cited in this article [1]

[38]	狄文, 张楠. 卵巢恶性肿瘤诊疗观念的思考与挑战[J]. 中国实用妇科与产科杂志, 2024, 40(11):1057-1060.DOI:10.19538/j.fk2024110101. Cited in this article [1]

[39]	全慧霞, 林仲秋. 妇科肿瘤人表皮生长因子受体2相关研究进展及检测方法[J]. 中国实用妇科与产科杂志, 2024, 40(01):74-84.DOI:10.19538/j.fk2024010117. Cited in this article [1]

[40]	彭澎, 向阳. 复发性卵巢癌的精准诊疗[J]. 中国实用妇科与产科杂志, 2024, 40(11):1069-1073.DOI:10.19538/j.fk2024110104. Cited in this article [1]

[41]	曾凯, 范相成, 胡悦欣, 等. 卵巢癌BRCA1/2基因突变中的大片段重排——全面基因检测的重要性[J]. 中国实用妇科与产科杂志, 2025, 41(10):1053-1056. DOI:10.19538/j.fk2025100120. Cited in this article [1]

[42]	刘倩, 周慧梅, 杨佳欣, 等. Ⅰ期卵巢透明细胞癌91例临床分析[J]. 中国实用妇科与产科杂志, 2025, 41(6):653-657.DOI:10.19538/j.fk2025060116. Cited in this article [1]